Pinned
1/n Now published in @NatureMedicine : The phase 2 #POLAR trial of pembrolizumab + olaparib maintenance in metastatic pancreatic cancer. @CpcrMsk @MSKCancerCenter @MSK_DeptOfMed @PICIatMSK
rdcu.be/e9WmJ
Wungki Park, MD MS
6,135 posts
Wungki Park, MD MS
@CentralParkWMD
Physician-Scientist | KRAS & DNA Repair | Translational Therapeutics | Founder, #sPARKlab (sparklaboratory.org) and #GRIT - GI RAS Innovative Therapeutics
- Pembro + olaparib maintenece #POLAR trial (B&C) in non-BRCA potential #HRD stage IV #PancreaticCancer n=30. Well-tolerated. 30% had no progression for > 6mo WITHOUT chemo. Deep science & POLAR A #BRCA awaited. #gratitude & 💜to MSK team & patients #ASCO23 t.ly/D9gl
- 🏃🏻♂️P2 study for pts w Locally Advanced #PancreaticCancer durvalumab with ablative radiation was safe and feasible. some interesting signal🤘🏼waging for 💜 @MSKCancerCenter @CpcrMsk panc team is here to cheer and walk with our patients. 🎉rockstar💫@ferguskeane2 #GI23 @ASCO
- My small thank you gift to all the grateful supporters. My family, friends, and patients. You rock and I got to finish the #marathon and want to share some #joy 💜 and #laugh from my #pain 😭 post #TCSNYCMarathon 🏃♂️#Finisher #legday #clip #PancreaticCancer @CpcrMsk @MSK_DeptOfMed
00:00 - @W_Park_MD @Jiapeng_Chen @xrtGenomics @EileenMOReilly are excited to share these data on behalf of our team including @MFBerger1 @TheVinodLab @ciacobu #PancreaticCancer #PancSM #HRD #DDR @CpcrMsk @Sloan_Kettering bit.ly/3cVY1al
- Join us for my oral presentation at #ASCO24 3:24 PM 6/1/2024 at Hall D1 in Chicago. 🤳@CentralParkWMD🕺🏻🪩 @ASCOPost Abstract 3002 #TF #ADC #PancreaticCancer #Developmental #Therapeutics @MSKCancerCenter 🙏 for all the pts Drs. @EileenMOReilly Zhang & Dayyani @RobinGuo5
GIF - IPI plus NIVO 44% ORR in pts with NON-pancreatic high-grade neuroendocrine carcinoma, with 0% ORR in low/intermediate grade disease. (DART SWOG 1609) Congratulations 🎉🎊 @PatelOncology @youngkwangchae @Dr_R_Kurzrock @CCR_AACR @AACR clincancerres.aacrjournals.org/content/early/…
- An #army of #force @ParkerICI against met #PancreaticCancer PRINCE trial: CD40 agonist, #nivolumab #gemcitabine #nab-paclitaxel ORR 54%. Congrats Mark O’Hara and Vonderheide @PennCancer and Eileen O’Reilly @sloan_kettering We are actively enrolling our patients for this trial
- #BiliaryTractCancer is a rare disease with poor prognosis. GemCisDurva is a new standard Tx #TOPAZ1 No definitive markers for response and resistance. Seeking immune exclusion markers from diff cells (AOI) at diff regions (ROI) by spatial transcriptomics #SITC23 @EileenMOReilly
- I am a medical oncologist at @sloan_kettering @CpcrMsk and I serve my #PancreaticCancer patients and develop clinical trials closely with @EileenMOReilly. My research focuses on #science translation of #genetics and #immunology from their cancers. @ciacobu #PancChat #PancSM
- Fellow oncologists, are you all offering germline testing to #PancreaticCancer patients? Emphasis on germline testing for all! by @Aiims1742 @MDAndersonNews We need to test other races like African Americans, Asians, and Latinos! #AACRPanCa19 #PancSM
- Clinical and immunological implications of frameshift mutations in lung cancer - A story of neoantigen beyond #TMB in #immunotherapy Congratulations to all the authors @JTOonline bit.ly/2XyqEFU
- Long-term follow up and 🧬genomic analysis on patients treated with adjuvant chemotherapy after surgery of their #PancreaticCancer #PDAC Congrats Dr. Moss @DrewMoss This shinning star 🌟 is an outstanding resident and is destined to succeed! Fantastic work! @MSK_DeptOfMed #ASCO24
